Published in Managed Care Business Week, May 10th, 2005
The results were published in the April 18, 2005, Journal of Clinical Oncology.
Researchers wrote, "Eligible breast cancer patients were naive to emetogenic chemotherapy and treated with cyclophosphamide±doxorubicin or epirubicin. Patients were randomly assigned to either an aprepitant [APR] regimen (day 1, APR 125 mg, ondansetron (OND) 8 mg, and dexamethasone 12 mg before chemotherapy...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Business Week